Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

A Prospective Clinical Trial of Boom-Boom Radiation As Bridging Therapy for Patients with Large B-Cell Lymphoma Undergoing Treatment with Lisocabtagene Maraleucel (Liso-cel) Therapy

Christopher R D'Angelo, Charles Enke, Julie M. Vose, Robert Gregory Bociek, Fang Yu, Makayla Schissel, Matthew Lunning

Blood (2024) 144 (Supplement 1): 3126.

https://doi.org/10.1182/blood-2024-208472

Published: 2024

Journal Articles

Impact of Icans on Long-Term Neurocognitive Function in Patients with Diffuse Large B-Cell Lymphoma Receiving CAR T-Cell Therapy

Olivia Leighton Makos, Valerie K Shostrom, James Olen Armitage, Julie M. Vose, Matthew Lunning, Robert Gregory Bociek, Christopher R D'Angelo

Blood (2024) 144 (Supplement 1): 2368.

https://doi.org/10.1182/blood-2024-194010

Published: 2024

Journal Articles

Long Term Follow up of Patients Undergoing High Dose Chemotherapy and Autologous or Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma

Sandra Frimpong, Valerie K Shostrom, Robert Gregory Bociek, Matthew Lunning, Christopher D' Angelo, James Olen Armitage, Julie M. Vose

Blood (2024) 144 (Supplement 1): 6327.

https://doi.org/10.1182/blood-2024-201621

Published: 2024

Journal Articles

Analysis of Surveillance Imaging and Outcomes for Relapsed CNS Lymphoma Using Novel Agents

Matthew Gromowsky, Shristi Upadhyay Banskota, Smriti Sharma, Robin High, Robert Gregory Bociek, Matthew Lunning, Julie M. Vose, Christopher D'Angelo

Blood (2024) 144 (Supplement 1): 7777.

https://doi.org/10.1182/blood-2024-206305

Published: 2024

Journal Articles

Patients with Private Insurance Endure Significantly Longer Delays in Time from Intent to CAR-T to Apheresis (Brain-2-Vein) in Multiple Treated Diffuse Large B-Cell Lymphoma: Analysis By Cellular Therapy Intent Quotient (CTIQ)

Matthew Gromowsky, Valerie Shostrom, Kimberly Schmidt-pokorny, James Olen Armitage, Julie M. Vose, Robert Gregory Bociek, Christopher D'Angelo, Matthew A Lunning

Blood (2023) 142 (Supplement 1): 258.

https://doi.org/10.1182/blood-2023-181344

Published: 2023

Journal Articles

Thrombosis Prophylaxis with Apixaban in Patients Treated with Asparaginase

Krishna Gundabolu, Vijaya R. Bhatt, Lynette M. Smith, Valerie K Shostrom, Lori J. Maness, Zaid S. Al-Kadhimi, Julie M. Vose, R. Gregory Bociek, Matthew A. Lunning, Avyakta Kallam, Christopher D'Angelo, Muhamed Baljevic, Apar K Ganti

Blood (2021) 138 (Supplement 1): 1069.

https://doi.org/10.1182/blood-2021-148945

Published: 2021

Journal Articles

Thirty-Five Year Follow-up Analysis of Follicular Lymphoma Patients Treated through the Nebraska Lymphoma Study Group: Prognostic Factor Analysis and Outcomes

Amulya Yellala, MBBS, Elizabeth R. Lyden, MS, Heather Nutsch, Avyakta Kallam, MD, Kai Fu, MD PhD, Timothy C. Greiner, MS, MD, Philip Bierman, MD, Matthew A. Lunning, DO, FACP, R. Gregory Bociek, MD, James O. Armitage, MD, Julie M. Vose, MD MBA

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-142743

Published: 2020

Journal Articles

A Single-Center Phase IIa Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Matthew A. Lunning, DO, Philip Bierman, MD, R. Gregory Bociek, MD, James O. Armitage, MD, Peggy Heires, R.N., Maribeth Hohenstein, R.N, Susan Blumel, RN, Jonathan Tefft, B.A., Elizabeth R. Lyden, MS, Michael R Green, PhD, Julie M. Vose, MD MBA

Blood (2018) 132 (Supplement 1): 5390.

https://doi.org/10.1182/blood-2018-99-119765

Published: 2018

Journal Articles

Combination of Umbralisib, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients with Advanced Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Matthew A. Lunning, DO, Philip Bierman, MD, R. Gregory Bociek, MD, Marshall T. Schreeder, MD, Tanya Siddiqi, MD, Christopher R Flowers, MD MS, Jonathon B. Cohen, MD MS, Susan Blumel, RN, Kathy Cutter, RN, Emily K. Pauli, BMBS,PharmD, Peter Sportelli, BS, Hari P Miskin, MSc, Michael S. Weiss, Julie M. Vose, MD MBA

Blood (2018) 132 (Supplement 1): 4197.

https://doi.org/10.1182/blood-2018-99-118917

Published: 2018

Journal Articles

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas, Paolo Caimi, Edward Agura, Jeffrey Matous, Stephen M. Ansell, Howland E. Crosswell, Miguel Islas-Ohlmayer, Caroline Behler, Eric Cheung, Andres Forero-Torres, Julie Vose, Owen A. O’Connor, Neil Josephson, Yinghui Wang, Ranjana Advani

Blood (2018) 132 (1): 40–48.

https://doi.org/10.1182/blood-2017-11-815183

Published: 2018

Includes: Supplemental data

Journal Articles

Phase I/II Trial of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Avyakta Kallam, MBBS, Jane Meza, PhD, Philip Bierman, MD, Matthew A. Lunning, DO, R. Gregory Bociek, MD, James Olen Armitage, MD, Julie M Vose, MD

Blood (2017) 130 (Supplement 1): 4039.

https://doi.org/10.1182/blood.V130.Suppl_1.4039.4039

Published: 2017

Journal Articles

Sequential Brentuximab Vedotin (Bv) before and after Adriamycin, Vinblastine, and Dacarbazine (Bv-AVD) for Older Patients with Untreated Classical Hodgkin Lymphoma (cHL): Final Results from a Multicenter Phase II Study

Andrew M Evens, DO,MSc, Ranjana H. Advani, MD, Michelle A. Fanale, MD, Sonali M. Smith, MD, Irene Helenowski, PhD, Borko Jovanovic, PhD, R. Gregory Bociek, MD, Andreas Klein, MD, Jane N. Winter, MD, Leo I. Gordon, MD, Paul A. Hamlin, MD

Blood (2017) 130 (Supplement 1): 733.

https://doi.org/10.1182/blood.V130.Suppl_1.733.733

Published: 2017

Journal Articles

Safety and Efficacy of Enoxaparin Prophylaxis in Adults Receiving Peg-Asparaginase Containing Induction Regimens for Acute Lymphoblastic Leukemia (ALL)

Jayadev Manikkam Umakanthan, MBBS, Lori J. Maness, MD, Jiangtao Luo, Avyakta Kallam, MBBS, James O. Armitage, MD, Philip Bierman, MD, Julie M. Vose, MD, R. Gregory Bociek, MD, Matthew Lunning, DO, Krishna Gundabolu, MD, Vijaya R. Bhatt, MD

Blood (2016) 128 (22): 5154.

https://doi.org/10.1182/blood.V128.22.5154.5154

Published: 2016

Journal Articles

Combination of Ublituximab, TGR-1202, and Bendamustine Demonstrates Significant Activity in Patients with Advanced DLBCL and Follicular Lymphoma

Matthew Lunning, DO, Philip J Bierman, MD, R. Gregory Bociek, MD, Marshall T. Schreeder, MD, Susan Blumel, RN, BSN, Kathy Cutter, RN, BSN, Emily K. Pauli, BMBS, PharmD, Peter Sportelli, Hari P. Miskin, MS, Michael S. Weiss, Julie M Vose, MD

Blood (2016) 128 (22): 4197.

https://doi.org/10.1182/blood.V128.22.4197.4197

Published: 2016

Journal Articles

Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL

Ashima Shukla, Karan Rai, Vipul Shukla, Nagendra K. Chaturvedi, R. Gregory Bociek, Samuel J. Pirruccello, Hamid Band, Runqing Lu, Shantaram S. Joshi

Blood (2016) 127 (19): 2310–2321.

https://doi.org/10.1182/blood-2015-09-669317

Published: 2016

Includes: Supplemental data

Journal Articles

An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL)

Anas Younes, MD, Gilles Salles, Giovanni Martinelli, R. Gregory Bociek, MD, Dolores Caballero Barrigon, MD, Eva Gonzalez Barca, Mehmet Turgut, MD PhD, John F. Gerecitano, MD, Fabian Herbst, Lisa Williams, Nabanita Mukherjee, Ranjana Tavorath, Won Seog Kim, MD PhD

Blood (2015) 126 (23): 1493.

https://doi.org/10.1182/blood.V126.23.1493.1493

Published: 2015

Journal Articles

Tolerability and Efficacy of Treatments in Elderly Patients with Hodgkin Lymphoma: A Report from the Nebraska Lymphoma Study Group

Roberto A. Ferro, MD, Vijaya R. Bhatt, MD, Martin Bast, BS, Lynette Smith, MS, R. Gregory Bociek, MD, Matthew A. Lunning, DO, Philip J Bierman, MD, Julie M. Vose, MD, James O. Armitage, MD

Blood (2015) 126 (23): 1504.

https://doi.org/10.1182/blood.V126.23.1504.1504

Published: 2015

Journal Articles

National Trend in Splenectomy for Splenic Marginal Zone Lymphoma (SMZL): An Analysis of Surveillance, Epidemiology and End Results (SEER) Database

Smith Giri, MBBS, Vijaya R. Bhatt, MD, Ranjan Pathak, MD, R. Gregory Bociek, MD, James O. Armitage, MD

Blood (2015) 126 (23): 5630.

https://doi.org/10.1182/blood.V126.23.5630.5630

Published: 2015

Journal Articles

Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma

Ann S. LaCasce, MD, Gregory Bociek, Ahmed Sawas, Paolo F. Caimi, MD, Edward Agura, Jeffrey Matous, Stephen Ansell, MD PhD, Howland Crosswell, MD, Miguel Islas-Ohlmayer, Caroline Behler, Eric Cheung, Andres Forero-Torres, Julie Vose, Owen A. O'Connor, MD, Neil Josephson, Ranjana Advani

Blood (2015) 126 (23): 3982.

https://doi.org/10.1182/blood.V126.23.3982.3982

Published: 2015

Journal Articles

Use of Low Molecular Weight Heparin (LMWH) in Thrombocytopenic Patients with Hematologic Malignancy-Associated Venous Thromboembolism (VTE)

Nabin Khanal, MBBS, R. Gregory Bociek, MD, Baojiang Chen, PhD, Julie M. Vose, MD, James O. Armitage, MD, Philip J Bierman, MD, Lori J. Maness, MD, Matthew A. Lunning, DO, Krishna Gundabolu, MD, Vijaya R. Bhatt, MD

Blood (2015) 126 (23): 3482.

https://doi.org/10.1182/blood.V126.23.3482.3482

Published: 2015

NARROW

A Prospective Clinical Trial of Boom-Boom Radiation As Bridging Therapy for Patients with Large B-Cell Lymphoma Undergoing Treatment with Lisocabtagene Maraleucel (Liso-cel) Therapy

Impact of Icans on Long-Term Neurocognitive Function in Patients with Diffuse Large B-Cell Lymphoma Receiving CAR T-Cell Therapy

Long Term Follow up of Patients Undergoing High Dose Chemotherapy and Autologous or Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma

Analysis of Surveillance Imaging and Outcomes for Relapsed CNS Lymphoma Using Novel Agents

Patients with Private Insurance Endure Significantly Longer Delays in Time from Intent to CAR-T to Apheresis (Brain-2-Vein) in Multiple Treated Diffuse Large B-Cell Lymphoma: Analysis By Cellular Therapy Intent Quotient (CTIQ)

Thrombosis Prophylaxis with Apixaban in Patients Treated with Asparaginase

Thirty-Five Year Follow-up Analysis of Follicular Lymphoma Patients Treated through the Nebraska Lymphoma Study Group: Prognostic Factor Analysis and Outcomes

A Single-Center Phase IIa Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Combination of Umbralisib, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients with Advanced Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

Phase I/II Trial of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Sequential Brentuximab Vedotin (Bv) before and after Adriamycin, Vinblastine, and Dacarbazine (Bv-AVD) for Older Patients with Untreated Classical Hodgkin Lymphoma (cHL): Final Results from a Multicenter Phase II Study

Safety and Efficacy of Enoxaparin Prophylaxis in Adults Receiving Peg-Asparaginase Containing Induction Regimens for Acute Lymphoblastic Leukemia (ALL)

Combination of Ublituximab, TGR-1202, and Bendamustine Demonstrates Significant Activity in Patients with Advanced DLBCL and Follicular Lymphoma

Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL

An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL)

Tolerability and Efficacy of Treatments in Elderly Patients with Hodgkin Lymphoma: A Report from the Nebraska Lymphoma Study Group

National Trend in Splenectomy for Splenic Marginal Zone Lymphoma (SMZL): An Analysis of Surveillance, Epidemiology and End Results (SEER) Database

Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma

Use of Low Molecular Weight Heparin (LMWH) in Thrombocytopenic Patients with Hematologic Malignancy-Associated Venous Thromboembolism (VTE)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only